Abamune-L Tablet

Abamune-L Tablet is a prescription antiretroviral medicine manufactured by Cipla Ltd. It is used in combination with other antiretroviral medicines to manage Human Immunodeficiency Virus type 1 (HIV-1) infection. The tablet contains two active pharmaceutical ingredients (APIs), Abacavir and Lamivudine, which work together to inhibit viral replication and help control HIV infection.

Abamune-L is designed to form part of a comprehensive HIV treatment regimen prescribed by a qualified healthcare professional. Consistent use, regular medical monitoring, and adherence to the prescribed treatment plan are important for maintaining viral suppression and supporting immune function.

Composition and Strength

Each Abamune-L Tablet contains the following active ingredients:

• Abacavir: 600 mg
• Lamivudine: 300 mg

The combined strength is 600 mg/300 mg per tablet. Abacavir and Lamivudine belong to the nucleoside reverse transcriptase inhibitor (NRTI) class of antiretroviral medicines.

Active Pharmaceutical Ingredients (APIs)

Abacavir works by inhibiting reverse transcriptase, an enzyme HIV uses to produce new copies of its genetic material. By interfering with this process, Abacavir helps reduce the virus’s ability to multiply.

Lamivudine is another nucleoside reverse transcriptase inhibitor. It interferes with HIV replication through a similar mechanism, complementing the activity of Abacavir.

Together, these two APIs help reduce the amount of HIV in the bloodstream, commonly measured as viral load. When used as part of an appropriate combination treatment, they can help preserve immune function and reduce the risk of HIV-related complications. Abamune-L does not cure HIV, so continued treatment and medical supervision remain essential.

Uses of Abamune-L Tablet

Abamune-L Tablet is primarily indicated for the treatment of HIV-1 infection as part of a complete antiretroviral regimen. Its clinical role includes:

• Helping reduce HIV viral load.
• Supporting the immune system by controlling viral replication.
• Helping maintain immune function during long-term HIV management.
• Reducing the risk of HIV-related complications when used consistently with an appropriate treatment plan.

The medicine must be selected according to the patient’s treatment history, clinical condition, and relevant laboratory results.

Recommended Dosage and Administration

The dosage of Abamune-L Tablet must be determined by the prescribing healthcare professional. For eligible adults, the commonly used regimen for the 600 mg Abacavir and 300 mg Lamivudine combination is one tablet once daily, as directed by the treating clinician.

The tablet is taken orally with water and may generally be taken with or without food. Patients should follow the instructions provided with their prescription and should not change the dose, discontinue treatment, or substitute another antiretroviral medicine without medical advice.

If a dose is missed, patients should follow their clinician’s or pharmacist’s instructions rather than taking extra tablets to compensate. The suitability of this fixed-dose combination may vary according to kidney function, liver health, age, and other clinical considerations.

Manufacturer and Packaging

• Brand name: Abamune-L Tablet
• Manufacturer/Marketer: Cipla Ltd.
• Dosage form: Oral tablet
• Strength: Abacavir 600 mg + Lamivudine 300 mg
• Therapeutic category: Antiretroviral medicine
• Typical pack size: 30 tablets, subject to market availability
• Prescription status: Prescription required

Safety Information and Precautions

Abamune-L may cause side effects such as nausea, headache, fatigue, diarrhoea, or vomiting. A serious allergic reaction to Abacavir is also possible. Patients should receive appropriate screening and counselling before starting treatment and seek urgent medical attention if they develop symptoms suggestive of a severe hypersensitivity reaction.

Inform the healthcare professional about existing medical conditions, pregnancy or breastfeeding, and all other medicines being taken. Regular monitoring may be required to assess treatment response and safety. Do not restart Abacavir after a suspected hypersensitivity reaction unless a specialist has explicitly determined that it is safe.

Storage Instructions

Store Abamune-L Tablet according to the manufacturer’s packaging instructions, away from excessive heat, moisture, and direct sunlight. Keep the medicine out of reach of children and do not use tablets beyond their stated expiry date.

Medical disclaimer: This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Use Abamune-L Tablet only under appropriate medical supervision.